Loading...
XSHG
600518
Market cap2.55bUSD
Jul 09, Last price  
1.25CNY
1D
0.00%
1Q
-28.98%
Jan 2017
-93.00%
IPO
9.59%
Name

Kangmei Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:600518 chart
P/E
1,673.71
P/S
3.30
EPS
0.00
Div Yield, %
—
Shrs. gr., 5y
24.47%
Rev. gr., 5y
-0.63%
Revenues
5.24b
+1.07%
825,607,0001,294,057,0001,727,164,0002,377,161,0003,308,802,0006,080,507,00011,165,154,81713,358,728,51615,949,188,76818,066,827,95221,642,324,06917,578,619,00017,065,079,13811,445,545,8095,412,008,0004,152,521,0984,180,150,3294,874,016,1425,189,137,1995,244,863,087
Net income
10m
+20.46%
99,889,000178,810,000294,575,000501,509,000715,523,0001,005,031,0001,441,191,4931,879,817,0002,285,879,1282,756,734,6063,340,403,6462,149,836,000374,492,329-4,660,675,027-31,084,832,0007,917,900,630-2,688,159,032102,521,2348,573,66910,327,997
CFO
111m
P
68,319,000162,553,0003,015,000119,466,000669,186,000574,964,0001,008,350,0001,674,011,0001,132,204,000508,863,0001,603,189,000-4,840,053,000305,617,0002,882,045,0001,031,392,000214,205,000-749,962,000-317,522,000-427,633,000111,346,627
Dividend
Aug 28, 20190.024 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese herbal medicines in China. The company offers Chinese patent medicines, chemical medicines, and health food products. In addition, it engages in the operation of Chinese medicinal materials markets; production and sale of medical devices; and operation of pharmaceutical logistics system. The company provides its products through medical institution resources, smart pharmacies, OTC retail, chain drug stores, direct sales, medical e-commerce, mobile medical care, etc. Kangmei Pharmaceutical Co., Ltd. was founded in 1997 and is based in Shenzhen, China.
URL
http://www.kangmei.com.cn/
IPO date
Mar 19, 2001
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT